基石药业-B(02616)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

02616 基石药业-B

已收盘 04-09 16:08:13

9.510

-0.040

-0.42%

最高9.710	最低9.390	成交量1,037万
今开9.600	昨收9.550	日振幅3.35%
总市值140.37亿	流通市值140.37亿	总股本14.76亿
成交额9,868万	换手率0.70%	流通股本14.76亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"02616","market":"HK","secType":"STK","nameCN":"基石药业-B","latestPrice":9.51,"timestamp":1775722093006,"preClose":9.55,"halted":0,"volume":10365820,"delay":0,"changeRate":-0.004188481675392767,"floatShares":1476000000,"shares":1476000000,"eps":-0.3606690524402663,"marketStatus":"已收盘","change":-0.04,"latestTime":"04-09 16:08:13","open":9.6,"high":9.71,"low":9.39,"amount":98684697,"amplitude":0.033508,"askPrice":9.51,"askSize":3500,"bidPrice":9.5,"bidSize":42000,"shortable":3,"etf":0,"ttmEps":-0.375849714061888,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1775784600000},"marketStatusCode":5,"adr":0,"listingDate":1551110400000,"exchange":"SEHK","adjPreClose":9.55,"openAndCloseTimeList":[[1775698200000,1775707200000],[1775710800000,1775721600000]],"volumeRatio":0.427171,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02616","defaultTab":"news","newsList":[{"id":"1184074392","title":"基石药业-B公布3月股份变动月报表，新增发行3,349股","url":"https://stock-news.laohu8.com/highlight/detail?id=1184074392","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1184074392?lang=zh_cn&edition=full","pubTime":"2026-04-09 19:02","pubTimestamp":1775732527,"startTime":"0","endTime":"0","summary":"基石药业-B于2026年4月9日发布截至2026年3月31日的股份变动月报表。公告显示，本月公司注册股本仍保持2,000,000,000股的水平，每股面值为USD 0.0001，注册股本总额USD 200,000，与上月无异动。根据月报，本月末公司已发行股份由上月的1,476,015,373股增至1,476,018,722股，较上月增加3,349股。2019年首次公开发售后员工持股计划于当月行权3,349股，募集资金总额为HKD 6,067.35。公告同时说明，本月内未发生股份回购或注销事宜。截至3月末，公司确认遵守香港联交所《上市规则》及相关法规要求。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02616"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625471449","title":"基石药业-B(02616.HK)遭GIC Private Limited减持252万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2625471449","media":"中金财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2625471449?lang=zh_cn&edition=full","pubTime":"2026-04-08 22:07","pubTimestamp":1775657222,"startTime":"0","endTime":"0","summary":"格隆汇4月8日丨根据联交所最新权益披露资料显示，2026年4月2日，基石药业-B(02616.HK)遭GIC Private Limited在场内以每股均价9.2282港元减持252万股，涉资约2325.51万港元。\r\n\r\n　　减持后，GIC Private Limited最新持股数目为8716.75万股，持股比例由6.08%下降至5.91%。","market":"sh","thumbnail":" http://caiji.3g.cnfol.com/colect/202604/08/20260408991586.jpg","type":0,"news_type":0,"thumbnails":[" http://caiji.3g.cnfol.com/colect/202604/08/20260408991586.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20260408/32132120.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["GIC","02616","BK1161","BK4104","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625996649","title":"招商证券国际：大升基石药业(02616)目标价至16.9港元 维持“增持”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2625996649","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2625996649?lang=zh_cn&edition=full","pubTime":"2026-04-08 10:46","pubTimestamp":1775616388,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，招商证券国际发布研报称，上调基石药业(02616)目标价131.5%，从7.3港元大升至16.9港元，维持“增持”评级。该行提高对PD-1/VEGF/CTLA-4 TsAb (CS2009)的资产估值，虽然该资产在未来临床开发存在不确定性，但该行认为公司管理层研发思路明确，战略清晰，也存在和海外大型药业开展深度合作的可能性。CS2009三抗有望突出重围。市场基于CS2009优异早期数据，正在重新定价并对BD开始预期。该行组织基石药业业绩后NDR，管理阶层对三抗分子Ph2剂量扩展与未来Ph3 MRCT充满信心。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1425747.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02616","EWH","06099"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1136590847","title":"异动解读 | 获两大外资机构看多，基石药业-B盘中大涨5.04%","url":"https://stock-news.laohu8.com/highlight/detail?id=1136590847","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1136590847?lang=zh_cn&edition=full","pubTime":"2026-03-30 13:36","pubTimestamp":1774848996,"startTime":"0","endTime":"0","summary":"基石药业-B今日盘中大涨5.04%，引起了市场的广泛关注。消息面上，杰富瑞和高盛两家知名外资机构发布研究报告，对基石药业核心在研产品CS2009的临床数据及其商业化前景给予积极评价，并均维持“买入”评级。报告指出，PD-1/VEGF/CTLA-4三特异性抗体CS2009在多项适应症中展现出突出的疗效与良好的安全性，有望成为公司未来对外授权及价值重估的重要驱动力。此外，机构也关注公司的ADC平台布局。这些积极的机构观点增强了市场对基石药业长期增长潜力的信心，从而推动了股价的显著上扬。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["02616"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623836457","title":"两大外资机构齐声看多基石药业(02616)：最高目标价看至20港元 CS2009成核心看点","url":"https://stock-news.laohu8.com/highlight/detail?id=2623836457","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2623836457?lang=zh_cn&edition=full","pubTime":"2026-03-30 09:21","pubTimestamp":1774833677,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，近期，多家国际投资机构发布研究报告，对基石药业-B核心在研产品CS2009的临床数据及其商业化前景给予积极评价。其中，杰富瑞维持“买入”评级，目标价20港元；高盛亦维持“买入”评级，目标价9.44港元。机构认为后线NSCLC患者ORR25%维持此前ESMO数据趋势，其IO经治数据显示CS2009具备一定“再激活免疫反应”的潜力。整体来看，两家机构普遍认为，在CS2009临床数据持续验证及BD潜力逐步释放的背景下，基石药业正迎来潜在估值重塑窗口。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1421479.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"两大外资机构齐声看多基石药业(02616)：最高目标价看至20港元 CS2009成核心看点","news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02616"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622446811","title":"基石药业-B午前涨幅扩大逾20% CS2009肺癌疗效数据亮眼","url":"https://stock-news.laohu8.com/highlight/detail?id=2622446811","media":"新浪港股","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622446811?lang=zh_cn&edition=full","pubTime":"2026-03-27 11:41","pubTimestamp":1774582860,"startTime":"0","endTime":"0","summary":"　　基石药业-B午前涨幅扩大逾20%，截至发稿，股价上涨20.29%，现报8.30港元，成交额3.90亿港元。　　基石药业公布，公司自主研发的PD-1/VEGF/CTLA-4三特异性抗体CS2009的最新临床进展。CS2009单药针对肺癌的I/II期初步疗效数据积极。　　基于以上结果，基石药业计划于2026年底前启动CS2009首批III期全球多中心临床试验，重点布局NSCLC、结直肠癌、小细胞肺癌等适应症。更多CS2009的I期和II期临床研究数据预计将于2026年在美国临床肿瘤学会年会和/或欧洲肿瘤内科学会年会上公布。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2026-03-27/doc-inhskwcy5489184.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1574","02616","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1169861203","title":"港股异动 | 生物医药股普涨，基石药业-B涨超13%，华领医药涨超11%","url":"https://stock-news.laohu8.com/highlight/detail?id=1169861203","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1169861203?lang=zh_cn&edition=full","pubTime":"2026-03-27 09:57","pubTimestamp":1774576637,"startTime":"0","endTime":"0","summary":"3月27日，生物医药股普涨，$基石药业-B(02616)$涨超13%，华领医药涨超11%，$开拓药业(09939)$、$来凯医药(02105)$、先瑞达医疗等多股涨超5%","market":"hk","thumbnail":"https://static.tigerbbs.com/fb4be1ff4aaa40ac88564f80f173158e","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/fb4be1ff4aaa40ac88564f80f173158e"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02616","BK1161","BK1191","BK4581","BK1574","02552","BK4585","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1152200438","title":"异动解读 | 基石药业-B盘中大涨7.39%，年度业绩亮眼及管线2.0重大突破成催化剂","url":"https://stock-news.laohu8.com/highlight/detail?id=1152200438","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1152200438?lang=zh_cn&edition=full","pubTime":"2026-03-27 09:51","pubTimestamp":1774576299,"startTime":"0","endTime":"0","summary":"基石药业-B今日盘中股价大幅上涨7.39%，引起了市场的高度关注。消息面上，公司发布了年度业绩报告，尽管收入有所波动，但研发投入显著增加，同比增长超过1.3倍，显示出公司对创新的坚定投入。舒格利单抗达成了两项重要的全球商业化合作协议，并在欧盟及英国获得了用于治疗III期非小细胞肺癌的监管批准。","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["02616"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622686874","title":"基石药业－Ｂ(02616.HK)2025年度营收2.7亿元  年内亏损4.37亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2622686874","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622686874?lang=zh_cn&edition=full","pubTime":"2026-03-26 21:07","pubTimestamp":1774530422,"startTime":"0","endTime":"0","summary":"格隆汇3月26日丨基石药业－Ｂ公布年度业绩，按国际财务报告准则，收入2024年度的人民币407.2百万元减少33.8%至2025年度的人民币2.696亿元。收入包括药品销售人民币7830万元、授权费收入人民币1.677亿元及舒格利单抗特许权使用费收入人民币2360万元。普拉替尼自2026年1月1日起纳入国家医保目录，预计其于2026年及以后的收入增长将抵消对2025年收入的短期负面影响。　　现金及现金等价物及定期存款截至2025年12月31日为人民币9.187亿元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20260326/32102143.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["02616"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622858900","title":"基石药业-B(02616)公布PD-1/VEGF/CTLA-4三特异性抗体CS2009的最新临床进展及I/II期关键临床数据","url":"https://stock-news.laohu8.com/highlight/detail?id=2622858900","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622858900?lang=zh_cn&edition=full","pubTime":"2026-03-26 17:09","pubTimestamp":1774516159,"startTime":"0","endTime":"0","summary":"智通财经APP讯，基石药业-B 公布公司自主研发的PD-1/VEGF/CTLA-4三特异性抗体CS2009的最新临床进展。在肺癌中展现强劲疗效：CS2009单药针对肺癌的I/II期初步疗效资料积极。截至2026年3月中旬，I期研究已共入组113例晚期实体瘤患者，中位元随访期约为6个月;II期研究已共入组85例患者。在TME中，PD-1和 CTLA-4的双重阻断作用通过与VEGFA的交联显著增强。同时，CS2009可优先结合PD-1和CTLA-4双阳性的肿瘤浸润T细胞，并最大程度上弱化对外周T细胞中CTLA-4调节通路的干扰。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1419507.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1169590202.USD","LU1169589451.USD","02616","BK1574","PD","BK4023","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622821058","title":"港股异动 | 基石药业-B(02616)再涨超4% 核心商业化产品舒格利单抗获ESMO指南【I, A】级推荐","url":"https://stock-news.laohu8.com/highlight/detail?id=2622821058","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622821058?lang=zh_cn&edition=full","pubTime":"2026-03-26 10:53","pubTimestamp":1774493593,"startTime":"0","endTime":"0","summary":"消息面上，3月25日，基石药业-B发布公告，公司核心商业化产品舒格利单抗获得欧洲肿瘤内科学会指南的级推荐。2025年2月，舒格利单抗联合化疗已获得ESMO《非驱动基因阳性转移性非小细胞肺癌动态临床指南》的推荐，用于鳞状及非鳞状IV期非小细胞肺癌双适应症的一线治疗。至此，舒格利单抗在欧盟及英国获批的两项肺癌适应症均已被纳入ESMO指南，充分体现了其临床价值。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1419292.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["VXUS","02616","BK1161","BK4588","BK4585","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622292100","title":"基石药业-B(02616)：舒格利单抗再获ESMO指南【I， A】推荐 ——用于III期非小细胞肺癌巩固治疗","url":"https://stock-news.laohu8.com/highlight/detail?id=2622292100","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622292100?lang=zh_cn&edition=full","pubTime":"2026-03-25 17:20","pubTimestamp":1774430400,"startTime":"0","endTime":"0","summary":"智通财经APP讯，基石药业-B 发布公告，公司核心商业化产品舒格利单抗获得欧洲肿瘤内科学会指南的级推荐。2025年2月，舒格利单抗联合化疗已获得ESMO《非驱动基因阳性转移性非小细胞肺癌动态临床指南》的推荐，用于鳞状及非鳞状IV期非小细胞肺癌双适应症的一线治疗。至此，舒格利单抗在欧盟及英国获批的两项肺癌适应症均已被纳入ESMO指南，充分体现了其临床价值。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1418760.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02616","III","BK4134","BK1574","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621825034","title":"港股异动 | 基石药业-B(02616)涨超4% 三项自主研发管线成果入选AACR 2026年会壁报展示环节","url":"https://stock-news.laohu8.com/highlight/detail?id=2621825034","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2621825034?lang=zh_cn&edition=full","pubTime":"2026-03-24 10:17","pubTimestamp":1774318678,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，基石药业-B(02616)涨超4%，截至发稿，涨3.05%，报6.41港元，成交额1818.43万港元。消息面上，近日，基石药业-B(02616)发布公告，本公司三项自主研发管线的临床前研究成果成功入选2026年美国癌症研究协会(AACR)年会壁报展示环节。该会议是全球癌症研究领域最具影响力的学术会议之一，本届年会将于2026年4月17日至22日在美国加利福尼亚州圣地牙哥会议中心隆重举行。相关研究摘要将于2026年4月3日在AACR官方期刊《Cancer Research》上发表。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1417818.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4588","BK4585","02616","BK1574","BK1161","VXUS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620401384","title":"基石药业-B(02616)将携三项自主研发管线成果亮相国际学术舞台","url":"https://stock-news.laohu8.com/highlight/detail?id=2620401384","media":"智通财经网","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620401384?lang=zh_cn&edition=full","pubTime":"2026-03-18 07:18","pubTimestamp":1773789521,"startTime":"0","endTime":"0","summary":"智通财经APP讯，基石药业-B(02616)发布公告，本公司三项自主研发管线的临床前研究成果成功入选2026年美国癌症研究协会(AACR)年会壁报展示环节。该会议是全球癌症研究领域最具影响力的学术会议之一，本届年会将于2026年4月17日至22日在美国加利福尼亚州圣地牙哥会议中心隆重举行。相关研究摘要将于2026 年4月3日在AACR官方期刊《Cancer Research》上发表。更多港股重磅资讯，下载智通财经app更多港股及海外理财资讯，请点击www.zhitongcaijing.com（搜索“智通财经”）；欲加入智通港股投资群，请加智通客服微信(ztcjkf)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1415174.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["02616","BK1161","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619616724","title":"每日卖空追踪 | 基石药业-B 03月13日卖空量成交151.55万股，卖空比例为18.7%","url":"https://stock-news.laohu8.com/highlight/detail?id=2619616724","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2619616724?lang=zh_cn&edition=full","pubTime":"2026-03-13 16:30","pubTimestamp":1773390632,"startTime":"0","endTime":"0","summary":"基石药业-B北京时间03月13日，跌0.28%，卖空量成交151.55万股，较上一交易日减少54.08%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260313163451a6bd1cd9&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260313163451a6bd1cd9&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1574","BK1161","02616"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617350920","title":"港股异动 | 基石药业-B(02616)再涨超9% 获纳入富时中国小盘股 三抗临床研究快速推进","url":"https://stock-news.laohu8.com/highlight/detail?id=2617350920","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617350920?lang=zh_cn&edition=full","pubTime":"2026-03-06 11:47","pubTimestamp":1772768878,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，基石药业-B(02616)再涨超9%，截至发稿，涨9.18%，报7.02港元，成交额7081.36万港元。消息面上，根据全球权威指数编制机构富时罗素（FTSE Russell）发布的富时全球股票指数系列（FTSE GEIS）半年度审议调整结果，基石药业成功获纳入富时中国小盘股指数成份股。相关调整将于2026年3月20日收盘后正式生效。国元国际指出，公司的PD-1/VEGF/CTLA-4 三抗安全性及疗效数据优秀，当前正在进行全球多中心二期临床研究，目前已入组200例患者，随着今年3月开始临床数据的逐步公布，有望达成重磅BD。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1410854.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["UWM","BK1161","IWO","BK4614","BK1574","BK4581","BK4588","MNQmain","RWM","SRTY","TZA","02616","TWM","BK4535","BK4585","BK4550","BK4534","IWN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1151451437","title":"港股异动 | 生物技术板块走强，药捷安康暴涨35%，百奥赛图涨14%","url":"https://stock-news.laohu8.com/highlight/detail?id=1151451437","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1151451437?lang=zh_cn&edition=full","pubTime":"2026-03-06 11:32","pubTimestamp":1772767952,"startTime":"0","endTime":"0","summary":"圣诺医药涨超11%，荣昌生物、基石药业涨超8%。","market":"hk","thumbnail":"https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"5137f1e9d165d819bc52e4abac894dbc","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02616","02257","02315","02617","09995"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617066845","title":"创新药板块强势 三生制药(01530)涨9.83% 机构指业绩兑现有望催化板块行情","url":"https://stock-news.laohu8.com/highlight/detail?id=2617066845","media":"金吾财讯","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617066845?lang=zh_cn&edition=full","pubTime":"2026-03-06 10:41","pubTimestamp":1772764875,"startTime":"0","endTime":"0","summary":"金吾财讯 | 创新药板块强势，三生制药 涨9.83%，基石药业-B涨6.84%，荣昌生物涨6.31%，映恩生物-B涨5.98%，四环医药涨5.76%，恒瑞医药涨5.77%，君圣泰医药-B涨5.58%，康诺亚-B涨5.31%，复宏汉霖涨5.02%。交银国际表示，本周各公司业绩预告陆续发布，该机构建议持续关注财务表现超预期、盈利路径清晰的公司，其业绩兑现有望催化板块行情。","market":"hk","thumbnail":"https://static.szfiu.com/news/20241108/MGQ5MWNhYjgxMjA0ZDU3OGI4Y2EzYTk1OWIyNGM1NTg2NTUyNjEzMTk5Ng==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/MGQ5MWNhYjgxMjA0ZDU3OGI4Y2EzYTk1OWIyNGM1NTg2NTUyNjEzMTk5Ng==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1976042","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2543165471.USD","09995","06978","LU0359201612.USD","00460","HK0000165453.HKD","BK1593","BK1161","HK0000500386.USD","159992","01530","LU1969619763.USD","09606","01276","02696","BK1574","HK0000252160.HKD","02162","LU0359201885.HKD","LU2328871848.SGD","BK1587","HK0000252152.HKD","HK0000306685.HKD","HK0000320264.USD","LU0359202008.SGD","BK1583","BK1600","LU1023057109.AUD","BK1191","02616","BK1515","HK0000306701.USD","HK0000320223.HKD","02511"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1188526290","title":"基石药业-B（02616）披露2月股份变动月报 新增发行8,532股","url":"https://stock-news.laohu8.com/highlight/detail?id=1188526290","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1188526290?lang=zh_cn&edition=full","pubTime":"2026-03-05 17:52","pubTimestamp":1772704341,"startTime":"0","endTime":"0","summary":"基石药业-B于2026年3月5日发布截至2026年2月28日的股份变动月报。公告显示，公司法定股本维持在2,000,000,000股，对应注册股本USD 200,000，报告期内未见增减变动。公司普通股方面，于2026年1月底已发行股份1,476,006,841股，2月新增发行8,532股，期末已发行股份合计1,476,015,373股。公告显示，当月并无库藏股，高管确认截至本月底公司已满足香港联交所规定的公众持股量要求。公司声明以上变动均遵照香港联交所《上市规则》及相关法律法规办理。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02616"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617733596","title":"港股异动 | 基石药业-B(02616)涨超12% 公司自研PD-1/VEGF/CTLA-4三抗有望达成重磅BD","url":"https://stock-news.laohu8.com/highlight/detail?id=2617733596","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617733596?lang=zh_cn&edition=full","pubTime":"2026-03-05 10:36","pubTimestamp":1772678196,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，基石药业-B涨超12%，截至发稿，涨12.71%，报6.65港元，成交额3695.43万港元。消息面上，基石药业-B此前发布公告称，公司核心资产CS2009用于晚期实体瘤的II期新药临床试验申请已经获得美国食品药品监督管理局批准。国元证券发布研报称，基石药业-B核心产品CS2009临床数据优异，安全性显著优于同类疗法，在IO经治NSCLC患者中ORR达17.6%，DCR达82.4%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1410300.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","BK4585","VXUS","02616","BK4588","VT","PD","BK4023","BK1574","LU1169589451.USD","LU1169590202.USD"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.cstonepharma.com","stockEarnings":[{"period":"1week","weight":0.0426},{"period":"1month","weight":0.4738},{"period":"3month","weight":0.6522},{"period":"6month","weight":0.4044},{"period":"1year","weight":3.3018},{"period":"ytd","weight":0.8121}],"compareEarnings":[{"period":"1week","weight":0.0237},{"period":"1month","weight":0.0191},{"period":"3month","weight":-0.0098},{"period":"6month","weight":-0.0151},{"period":"1year","weight":0.2864},{"period":"ytd","weight":0.0102}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"基石药业是一家主要从事肿瘤、自身免疫和炎症及其他关键疾病领域药物研发及销售的投资控股公司。该公司通过其子公司主要从事生物制药产品的研发、药品的销售及提供其知识产权（IP）授权或商业化授权。该公司产品主要包括精准治疗药物“泰吉华”（阿伐替尼）及“普吉华”（普拉替尼）、以及“择捷美”（舒格利单抗）等。该公司还从事肿瘤免疫药物的开发及商业化。该公司主要在中国国内市场、以及中欧、东欧和瑞士等海外市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.714286,"avgChangeRate":-0.050688},{"month":2,"riseRate":0.428571,"avgChangeRate":0.069097},{"month":3,"riseRate":0.25,"avgChangeRate":-0.053883},{"month":4,"riseRate":0.285714,"avgChangeRate":-0.027266},{"month":5,"riseRate":0.5,"avgChangeRate":0.100514},{"month":6,"riseRate":0.714286,"avgChangeRate":0.09443},{"month":7,"riseRate":0.571429,"avgChangeRate":0.05639},{"month":8,"riseRate":0.428571,"avgChangeRate":0.079119},{"month":9,"riseRate":0.428571,"avgChangeRate":-0.071005},{"month":10,"riseRate":0.428571,"avgChangeRate":-0.012196},{"month":11,"riseRate":0.571429,"avgChangeRate":0.010396},{"month":12,"riseRate":0.428571,"avgChangeRate":0.004524}],"exchange":"SEHK","name":"基石药业-B","nameEN":"CSTONE PHARMA-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.40.0","shortVersion":"4.40.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"基石药业-B(02616)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供基石药业-B(02616)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"基石药业-B,02616,基石药业-B股票,基石药业-B股票老虎,基石药业-B股票老虎国际,基石药业-B行情,基石药业-B股票行情,基石药业-B股价,基石药业-B股市,基石药业-B股票价格,基石药业-B股票交易,基石药业-B股票购买,基石药业-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"基石药业-B(02616)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供基石药业-B(02616)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}